02.03.2017 01:11 Uhr, Quelle: Presseportal

ALK Announces FDA Approval for its House Dust Mite Sublingual Allergy Immunotherapy Tablet (ACARIZAX® in Europe)

ALK: Hørsholm, Denmark (ots/PRNewswire) - ALK (ALKB:DC (http://alk-b.co/) / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for its house dust mite (HDM)

Weiterlesen bei Presseportal